Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ: GLUE ) with a Buy and raises the price target from $30 to $35.